Status:
WITHDRAWN
Isolation of Cells From Biopsy Tissue to Aid in Kidney Repair
Lead Sponsor:
Brigham and Women's Hospital
Conditions:
Kidney Diseases
Endothelial Dysfunction
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
Brief Summary
Endothelial progenitor cells that reside in renal vasculature may be stimulated to initiate differentiation programs during episodes of injury. It is hypothesized that endothelial progenitor cells res...
Detailed Description
Endothelial dysfunction is central to the pathophysiology of vascular ischemia, bacterial sepsis, toxin-induced thrombotic microangiopathy, and antibody-mediated kidney transplant rejection and often ...
Eligibility Criteria
Inclusion
- Only patients who have a clinical indication for kidney biopsy will be considered.
- All subjects will be at least 18 years of age and may be of any gender.
- Patients undergoing a native or kidney transplant biopsy will be considered.
Exclusion
- Patients not undergoing a kidney biopsy will be excluded.
Key Trial Info
Start Date :
January 21 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2024
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04896567
Start Date
January 21 2022
End Date
December 30 2024
Last Update
August 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115